Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Merck regulatory update

July 17, 1995 7:00 AM UTC

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended the approval of Fosamax (alen-dronate) to preserve bone density and prevent fractures. Merck (Whitehouse Station, N.J.) sai...